Fida Biosystems (Fidabio), a company specializing in advanced biomolecular analysis, has successfully raised $5.0 million in new funding. This capital infusion marks a significant milestone for Fidabio as it continues to develop and deploy its proprietary technology designed for direct, transparent, and in-solution characterization of biomolecules.
Fidabio's platform offers absolute measurements of hydrodynamic radius, enabling precise characterization and quantification of proteins and nanoparticles ranging from 0.5 to 1,000 nm Dh. This includes critical biological entities such as antibodies, exosomes, liposomes, and membrane proteins. The technology provides detailed insights into affinity (Kd), kinetics (kon & koff), size, concentration, stoichiometry, conformational changes, and oligomeric state. A key differentiator is its ability to operate directly in complex biological samples like plasma, serum, or cell lysate, without the need for surface immobilization. This approach eliminates non-specific binding artifacts and simplifies assay development, ensuring that true binding events are accurately measured.
The newly secured $5.0 million will be instrumental in accelerating Fidabio's strategic growth initiatives. The company plans to allocate the funds towards enhancing its research and development efforts, expanding its commercial operations, and scaling its market presence. This investment underscores confidence in Fidabio's innovative approach to biomolecular analysis, which offers a fast, sample-efficient, and matrix-tolerant solution with integrated quality control and automation.
By providing transparent, absolute data for applications in research, development, and manufacturing, Fidabio aims to empower scientists and researchers to make more confident decisions. The company is poised to further advance its mission of delivering measurements that accurately reflect biological reality, thereby supporting critical advancements across the life sciences industry.
.png&w=3840&q=75)
